AB 225
Alternative Names: AB-225Latest Information Update: 09 Feb 2024
Price :
$50 *
At a glance
- Originator Angiocrine Bioscience
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Transplant rejection
- No development reported Intervertebral disc degeneration; Spinal cord injuries
Most Recent Events
- 09 Feb 2024 Preclinical trials in Transplant rejection in USA (Parenteral) (Angiocrine biosciences pipeline, February 2024)
- 28 Nov 2023 No recent reports of development identified for research development in Intervertebral-disc-degeneration in USA (Parenteral)
- 28 Nov 2023 No recent reports of development identified for research development in Spinal-cord-injuries in USA (Parenteral)